MINERVA NEUROSCIENCES INC (NERV) Stock Fundamental Analysis

NASDAQ:NERV • US6033802058

6.34 USD
-0.11 (-1.71%)
At close: Feb 19, 2026
6.22 USD
-0.12 (-1.89%)
After Hours: 2/19/2026, 8:19:44 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, NERV scores 2 out of 10 in our fundamental rating. NERV was compared to 521 industry peers in the Biotechnology industry. Both the profitability and financial health of NERV have multiple concerns. NERV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NERV has reported negative net income.
  • NERV had a negative operating cash flow in the past year.
  • In multiple years NERV reported negative net income over the last 5 years.
  • NERV had a negative operating cash flow in each of the past 5 years.
NERV Yearly Net Income VS EBIT VS OCF VS FCFNERV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • NERV's Return On Assets of -49.93% is in line compared to the rest of the industry. NERV outperforms 50.67% of its industry peers.
Industry RankSector Rank
ROA -49.93%
ROE N/A
ROIC N/A
ROA(3y)-35.71%
ROA(5y)-33.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NERV Yearly ROA, ROE, ROICNERV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

  • NERV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NERV Yearly Profit, Operating, Gross MarginsNERV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 1 2 3 4

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • NERV has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, NERV has more shares outstanding
  • NERV has a worse debt/assets ratio than last year.
NERV Yearly Shares OutstandingNERV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
NERV Yearly Total Debt VS Total AssetsNERV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -18.80, we must say that NERV is in the distress zone and has some risk of bankruptcy.
  • NERV has a Altman-Z score of -18.80. This is amonst the worse of the industry: NERV underperforms 81.96% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.8
ROIC/WACCN/A
WACCN/A
NERV Yearly LT Debt VS Equity VS FCFNERV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • NERV has a Current Ratio of 4.87. This indicates that NERV is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 4.87, NERV is in line with its industry, outperforming 55.66% of the companies in the same industry.
  • A Quick Ratio of 4.87 indicates that NERV has no problem at all paying its short term obligations.
  • With a Quick ratio value of 4.87, NERV perfoms like the industry average, outperforming 56.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 4.87
NERV Yearly Current Assets VS Current LiabilitesNERV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • NERV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.55%, which is quite impressive.
EPS 1Y (TTM)31.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-112.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.95% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.15%
EPS Next 2Y32.5%
EPS Next 3Y21.96%
EPS Next 5Y16.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NERV Yearly Revenue VS EstimatesNERV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2028 2029 2030 2031 50M 100M 150M 200M 250M
NERV Yearly EPS VS EstimatesNERV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NERV. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NERV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NERV Price Earnings VS Forward Price EarningsNERV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NERV Per share dataNERV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NERV's earnings are expected to grow with 21.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.5%
EPS Next 3Y21.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NERV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MINERVA NEUROSCIENCES INC

NASDAQ:NERV (2/19/2026, 8:19:44 PM)

After market: 6.22 -0.12 (-1.89%)

6.34

-0.11 (-1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-10
Inst Owners28.5%
Inst Owner Change506.78%
Ins Owners4.02%
Ins Owner Change0%
Market Cap274.33M
Revenue(TTM)N/A
Net Income(TTM)-14.03M
Analysts45.71
Price Target4.59 (-27.6%)
Short Float %0.96%
Short Ratio5.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-172.73%
EPS NY rev (1m)0%
EPS NY rev (3m)40.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.32
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS-0.8
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.93%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.71%
ROA(5y)-33.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.87
Quick Ratio 4.87
Altman-Z -18.8
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-112.19%
EPS Next Y51.15%
EPS Next 2Y32.5%
EPS Next 3Y21.96%
EPS Next 5Y16.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y40.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.05%
OCF growth 3YN/A
OCF growth 5YN/A

MINERVA NEUROSCIENCES INC / NERV FAQ

Can you provide the ChartMill fundamental rating for MINERVA NEUROSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to NERV.


What is the valuation status of MINERVA NEUROSCIENCES INC (NERV) stock?

ChartMill assigns a valuation rating of 1 / 10 to MINERVA NEUROSCIENCES INC (NERV). This can be considered as Overvalued.


How profitable is MINERVA NEUROSCIENCES INC (NERV) stock?

MINERVA NEUROSCIENCES INC (NERV) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for NERV stock?

The Earnings per Share (EPS) of MINERVA NEUROSCIENCES INC (NERV) is expected to grow by 51.15% in the next year.